Stephen V Liu, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“In this latest episode of the IASLC podcast, Lung Cancer Considered, I discuss the latest FDA approval for lung cancer: zidesamtinib for advanced ROS1 NSCLC with Drs. Alexander Drilon and Charo Campelo.
How does this shake up the landscape?
Listen now: FDA Approval: Zidesamtinib and ROS1 NSCLC.”
Other articles about NSCLC on OncoDaily.